<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894373</url>
  </required_header>
  <id_info>
    <org_study_id>HWD301</org_study_id>
    <nct_id>NCT01894373</nct_id>
  </id_info>
  <brief_title>Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis</brief_title>
  <official_title>Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to determine the therapeutic roles of CIK cells on patients with psoriasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>therapeutic roles of CIK on psoriasis</measure>
    <time_frame>1 year</time_frame>
    <description>changes of area and extent of skin lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>within 2 weeks</time_frame>
    <description>adverse effect after CIK cell infusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>infiltration of immune cells under skin</measure>
    <time_frame>6 months</time_frame>
    <description>aberrant infiltration of immune cells within the full-thickness of skin by skin biopsy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Psoriasis</condition>
  <condition>Adoptive Immunotherapy</condition>
  <arm_group>
    <arm_group_label>CIK, psoriasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adoptive Immunotherapy</intervention_name>
    <description>Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells</description>
    <arm_group_label>CIK, psoriasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK</intervention_name>
    <arm_group_label>CIK, psoriasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis&#xD;
             and be a candidate for treatment with CIK Are being treated with or initiating CIK&#xD;
             therapy at the time of enrollment Be able to provide written informed consent Be&#xD;
             willing and able to fully to participate for the duration of patient follow-up (5&#xD;
             years)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PUVA or Grenz ray therapy within 4 weeks prior to randomisation. UVB therapy within 2&#xD;
             weeks prior to randomisation. Systemic treatment with biological therapies (marketed&#xD;
             or otherwise) with a possible effect on psoriasis (e.g., alefacept, efalizumab,&#xD;
             etanercept, infliximab) within 3 months prior to randomisation.&#xD;
&#xD;
        Systemic treatment other than biologicals with a possible effect on psoriasis (e.g.,&#xD;
        corticosteroids, vitamin D analogues, retinoids, hydroxycarbamide, azathioprine,&#xD;
        meth-otrexate, cyclosporine, other immunosuppressants) within 4 weeks prior to&#xD;
        randomisation.&#xD;
&#xD;
        Any topical treatment of the scalp (except for medicated shampoos and emollients) within 2&#xD;
        weeks prior to randomisation (medicated shampoos/emollients are not allowed during the&#xD;
        double-blind phase). Shampoos containing corticosteroids, e.g. Clobex®, are not allowed&#xD;
        within 2 weeks prior to randomisation.&#xD;
&#xD;
        Planned use of topical treatment for psoriasis of the trunk or limbs, besides study&#xD;
        medication, during the study with the exceptions of: • emollient • medications used to&#xD;
        treat psoriasis of the skin folds and/or genitals (any medication may be used for this&#xD;
        purpose apart from Class 1-5 corticosteroids.&#xD;
&#xD;
        Topical treatment of the face with Class 1-5 corticosteroids within 2 weeks prior to&#xD;
        randomisation.&#xD;
&#xD;
        Planned initiation of, or changes to, concomitant medication that could affect psoriasis&#xD;
        (e.g., beta blockers, anti-malaria drugs, lithium) during the double-blind phase of the&#xD;
        study.&#xD;
&#xD;
        Treatment with any non-marketed drug substance (i.e., an agent which has not yet been made&#xD;
        available for clinical use following registration) within 4 weeks prior to randomisation.&#xD;
&#xD;
        Planned use of chemical treatments of the hair (eg relaxers, 'perms', or colourings) during&#xD;
        the double-blind phase of the study.&#xD;
&#xD;
        Current diagnosis of erythrodermic, exfoliative or pustular psoriasis. Patients with any of&#xD;
        the following conditions also present on psoriatic areas of the scalp or trunk/limbs: viral&#xD;
        (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections,&#xD;
        parasitic infections, skin manifestations in relation to tuberculosis or syphilis, rosacea,&#xD;
        acne rosacea, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins,&#xD;
        ichthyosis, ulcers or wounds.&#xD;
&#xD;
        Other inflammatory skin diseases that may confound the evaluation of psoriasis of the scalp&#xD;
        or trunk/limbs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han weidong, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Institute of immunology，Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>May 13, 2018</last_update_submitted>
  <last_update_submitted_qc>May 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

